# Shanghai Biotech

China’s Biocone Seeks to Revolutionize Drug Manufacturing with ‘Biological Lithography’

Biocone is industrializing cell-free protein synthesis, a technology dubbed 'biological lithography' that bypasses traditional cell-based manufacturing to produce high-purity proteins and artificial blood. Backed by Shanghai’s strategic industrial policies, the company has scaled production capacity to 60,000 tons, aiming to achieve self-reliance in the critical infrastructure of global biopharmaceutics.